| Ytd | 91.77% | |
| 1y | 60.67% |
| Open | 16.85 | Prev Close | 16.92 | Low | 16.72 | High | 17.83 | Mkt Cap | 2.41B |
| Vol | 3.72M | Avg Vol | 6.54M | EPS | -3.52 | P/E | N/A | Forward P/E | -9.57 |
| Beta | 1.81 | Short Ratio | 7.65 | Inst. Own | 76.84% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 14.05 | 200-d Avg | 13.65 | 1yr Est | 26.63 |
NTLA News
It might pull it off, provided several things fall right in place.
Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpar
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names whe
U.S. stocks rose, with the Dow Jones gaining 200 points on Wed. Jabil Inc (JBL) shares surged 9.8% a
Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outp
Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral
Intellia shares rise after new Phase 3 lonvo-z data showed significant reductions in HAE attacks and
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Intellia Therapeutics (NASDAQ:NTLA)
Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European A
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolution
Intellia will also have a poster presentation detailing the burdens experienced by HAE patients livi